Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
about
Determinants of mortality in patients with type 2 diabetes: a review.Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort StudyRisk factors for cancer development in type 2 diabetes: A retrospective case-control studyAssociation of Genomic Instability with HbA1c levels and Medication in Diabetic Patients.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Calculated Daily Insulin Dosages Overestimate Prescribed Insulin Doses in Type 2 Diabetes: A Primary Care Database Study.Incidence of cancer in patients with chronic heart failure: a long-term follow-up study.Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study.Cardiovascular safety of insulin: Between real-world data and reality.Doing it hard in the bush: Aligning what gets measured with what matters.Physical activity and Type 1 diabetes: an underused therapy.Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus.Relationship of Hyperglycaemia, Hypoglycaemia, and Glucose Variability to Atherosclerotic Disease in Type 2 Diabetes
P2860
Q35986709-1F71BAAC-D561-4443-8E80-BE7D6326C888Q36010556-0B59159F-B7BA-4ADB-B843-8A487A7DEACCQ36159846-C8E45C60-BF7E-40E8-BC73-ED06A8E437D8Q37620728-25D9BDD6-0522-4850-967C-A699EF6238CCQ38841043-CA0E3231-FFD7-4414-B180-B1F78D1A61AAQ38903844-73729268-8C60-41FF-9E76-8EFBBFF1B524Q40987649-59DFA153-98B6-4468-832E-916F80397D65Q41888320-85303C89-C39A-470A-B3BD-BAE55472ED78Q45895265-3FA0AEE3-5119-418B-904C-B22D88535D81Q47987963-96990B58-4FDE-471D-8E59-125ACFA9425BQ48266832-6CD80643-F44E-44BC-8CAF-67E01BA79662Q48274043-C1435A78-2B99-450F-9E86-5435971E60E4Q48296619-01818B8B-B347-4251-B08E-6CFD9044D9D5Q55024341-E0EE78BA-7DAE-4E5C-A88B-484E9CB8E9F1Q58839340-6E074BDB-40DF-4940-AD9C-4620339F0D46
P2860
Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Glucose-lowering with exogenou ...... diovascular events and cancer.
@en
Glucose-lowering with exogenou ...... diovascular events and cancer.
@nl
type
label
Glucose-lowering with exogenou ...... diovascular events and cancer.
@en
Glucose-lowering with exogenou ...... diovascular events and cancer.
@nl
prefLabel
Glucose-lowering with exogenou ...... diovascular events and cancer.
@en
Glucose-lowering with exogenou ...... diovascular events and cancer.
@nl
P2093
P2860
P356
P1476
Glucose-lowering with exogenou ...... diovascular events and cancer.
@en
P2093
C J Currie
C Ll Morgan
G Schernthaner
S E Holden
P2860
P304
P356
10.1111/DOM.12412
P577
2014-12-10T00:00:00Z